OR WAIT 15 SECS
Adalimumab (Humira, Abbott) is now approved for a second indication for use by patients with moderately to severely active Crohn's disease who are not responding to conventional therapy to reduce signs and symptoms and induce and maintain clinical remission. The new approval was based on results from three clinical trials in more than 1,400 adult patients and evaluated the efficacy of adalimumab in patients who were naive to anti-tumor necrosis factor alpha therapy. According to Abbott, this approval marks the indication to launch with the Humira Pen, a method of self-injection approved by the FDA in June 2006. Adalimumab was previously approved for reducing the signs and symptoms and inducing clinical remission in patients who have lost response or have become intolerant to infliximab (Remicade, Centocor).